National News

Valeant to sell assets to Nestle for $1.4B

By The Canadian Press

LAVAL, Que. - Valeant Pharmaceuticals International, Inc. ((TSX:VRX) says it has agreed to sell the rights to five products to Nestle S.A. for $1.4 billion.

Laval, Que.-based Valeant says Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma.

The transaction is subject to customary closing conditions and Valeant says it is not contingent upon a successful transaction with Botox-maker Allergan, Inc.

Valeant has made a hostile takeover offer for California-based Allergan, which fired back Tuesday by saying Valeant's growth is overstated and questioned its ability to cut US$2.7 billion of expenses if it acquires the company.

The broadside came ahead of what is expected to be an improved offer from Valeant on Wednesday.

"We are pleased to enter into this transaction," said Valeant chairman and CEO J. Michael Pearson, adding Galderma is "firmly committed to the aesthetic dermatology."

The five anti-aging skin treatments being sold by Valeant are Restylane, Perlane, Emervel, Sculptra and Dysport.

We encourage an open exchange of ideas on this story's topic, but we ask you to follow our guidelines for respecting community standards. Personal attacks, inappropriate language, and off-topic comments may be removed, and comment privileges revoked, per our Terms of Use. Please see our FAQ if you have questions or concerns about using Facebook to comment.

You might like ...

Liquor changes could push up prices
 
The New Mayor and Councillors
 
Bedtime Rhymes Pantomime brings fairy tales to life
School District 8 implements anti-violence protocols
 
Twin accidents at Grohman Narrows
 
Flu vaccine less effective against mutant strain

Community Events, November 2014

Add an Event


Read the latest eEdition

Browse the print edition page by page, including stories and ads.

Nov 20 edition online now. Browse the archives.